Cidofovir dihydrateAntiviral agent for CMV CAS# 149394-66-1 |
- kb NB 142-70
Catalog No.:BCC1675
CAS No.:1233533-04-4
Quality Control & MSDS
Number of papers citing our products
Chemical structure
3D structure
| Cas No. | 149394-66-1 | SDF | Download SDF |
| PubChem ID | 60933 | Appearance | Powder |
| Formula | C8H18N3O8P | M.Wt | 315.22 |
| Type of Compound | N/A | Storage | Desiccate at -20°C |
| Synonyms | HPMPC dihydrate; (S)-HPMPC dihydrate | ||
| Solubility | Soluble in DMSO | ||
| Chemical Name | [(2S)-1-(4-amino-2-oxopyrimidin-1-yl)-3-hydroxypropan-2-yl]oxymethylphosphonic acid;dihydrate | ||
| SMILES | C1=CN(C(=O)N=C1N)CC(CO)OCP(=O)(O)O.O.O | ||
| Standard InChIKey | FPKARFMSZDBYQF-ILKKLZGPSA-N | ||
| Standard InChI | InChI=1S/C8H14N3O6P.2H2O/c9-7-1-2-11(8(13)10-7)3-6(4-12)17-5-18(14,15)16;;/h1-2,6,12H,3-5H2,(H2,9,10,13)(H2,14,15,16);2*1H2/t6-;;/m0../s1 | ||
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
| About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
| Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. | ||
| Description | Cidofovir dehydrate is an injectable antiviral medication for the treatment of cytomegalovirus (CMV) retinitis, which suppresses virus replication by selective inhibition of viral DNA synthesis.
Target: CMV DNA polymerase
Cidofovir is an injectable antiviral medication for the treatment of cytomegalovirus (CMV) retinitis in patients with AIDS. It suppresses CMV replication by selective inhibition of viral DNA polymerase and therefore prevention of viral replication and transcription. It is an acyclic nucleoside phosphonate, and is therefore independent of phosphorylation by viral enzymes, unlike acyclovir.
Cidofovir was discovered at the Institute of Organic Chemistry and Biochemistry, Prague, by Antonín Hol?, and developed by Gilead Sciences and is marketed with the brand name Vistide by Gilead in the USA, and by Pfizer elsewhere. Maintenance therapy with cidofovir involves an infusion only once every two weeks, making it a convenient treatment option. Because dosing is relatively infrequent, a permanent catheter is not necessary for infusions. References: | |||||
Cidofovir dihydrate Dilution Calculator
Cidofovir dihydrate Molarity Calculator
| 1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
| 1 mM | 3.1724 mL | 15.8619 mL | 31.7239 mL | 63.4478 mL | 79.3097 mL |
| 5 mM | 0.6345 mL | 3.1724 mL | 6.3448 mL | 12.6896 mL | 15.8619 mL |
| 10 mM | 0.3172 mL | 1.5862 mL | 3.1724 mL | 6.3448 mL | 7.931 mL |
| 50 mM | 0.0634 mL | 0.3172 mL | 0.6345 mL | 1.269 mL | 1.5862 mL |
| 100 mM | 0.0317 mL | 0.1586 mL | 0.3172 mL | 0.6345 mL | 0.7931 mL |
| * Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. | |||||
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
Cidofovir dehydrate is an injectable antiviral medication for the treatment of cytomegalovirus (CMV) retinitis, which suppresses virus replication by selective inhibition of viral DNA synthesis.
- UNC2881
Catalog No.:BCC5362
CAS No.:1493764-08-1
- 1,2,3,4,6-O-Pentagalloylglucose
Catalog No.:BCN2338
CAS No.:14937-32-7
- UNC2250
Catalog No.:BCC4876
CAS No.:1493694-70-4
- AACOCF3
Catalog No.:BCC7075
CAS No.:149301-79-1
- Cytochalasin B
Catalog No.:BCN7084
CAS No.:14930-96-2
- pp60 c-src (521-533) (phosphorylated)
Catalog No.:BCC5851
CAS No.:149299-77-4
- 1-Dehydroxy-23-deoxojessic acid
Catalog No.:BCN1663
CAS No.:149252-87-9
- De-4'-O-methylyangambin
Catalog No.:BCN1662
CAS No.:149250-48-6
- Neotripterifordin
Catalog No.:BCN7477
CAS No.:149249-32-1
- Arcaine sulfate
Catalog No.:BCC6631
CAS No.:14923-17-2
- Z-Ser(Tos)-OMe
Catalog No.:BCC2741
CAS No.:1492-52-0
- H-Abu-OH
Catalog No.:BCC3198
CAS No.:1492-24-6
- NE 100 hydrochloride
Catalog No.:BCC7573
CAS No.:149409-57-4
- Poncirin
Catalog No.:BCN2590
CAS No.:14941-08-3
- Traxillaside
Catalog No.:BCN6917
CAS No.:149415-62-3
- Hypocrellin C
Catalog No.:BCN3398
CAS No.:149457-83-0
- Ganoderic acid AM1
Catalog No.:BCN2441
CAS No.:149507-55-1
- Marmin
Catalog No.:BCN1665
CAS No.:14957-38-1
- Stachybotramide
Catalog No.:BCN6969
CAS No.:149598-71-0
- Impentamine dihydrobromide
Catalog No.:BCC7197
CAS No.:149629-70-9
- MOG (35-55)
Catalog No.:BCC3670
CAS No.:149635-73-4
- Vorinostat (SAHA, MK0683)
Catalog No.:BCC2145
CAS No.:149647-78-9
- Nafadotride
Catalog No.:BCC7025
CAS No.:149649-22-9
- Chrysosplenol D
Catalog No.:BCN1666
CAS No.:14965-20-9
Cyclic HPMPC is safe and effective against systemic guinea pig cytomegalovirus infection in immune compromised animals.[Pubmed:10996398]
Antiviral Res. 2000 Aug;47(2):103-9.
Cidofovir (HPMPC) is licensed for the treatment of cytomegalovirus (CMV) retinitis in patients with AIDS but its use is limited by nephrotoxicity. We evaluated the safety and efficacy of 1-[((s)-2-hydroxy-2-oxo-1,4,2-dioxaphosphorinan-5-yl)methyl]cytosi ne dihydrate (CHPMPC) the cyclic congener of cidofovir. Treatment was well tolerated both in normal guinea pigs and in animals immune compromised with cyclophosphamide. Further, blood chemistry analysis showed no adverse effects of CHPMPC treatment on kidney or liver function. In efficacy studies in immune compromised guinea pigs challenged with a virulent salivary gland passaged guinea pig CMV, CHPMPC treatment significantly reduced mortality resulting from disseminated virus infection. Quantitative culture showed that treatment also significantly reduced virus replication in the liver and spleen, but not the lungs of infected animals. The efficacy of CHPMPC combined with its improved safety profile appear to make it an attractive alternative to cidofovir for the treatment of herpesvirus infections. Further evaluation is warranted.
Biochemical basis for increased susceptibility to Cidofovir of herpes simplex viruses with altered or deficient thymidine kinase activity.[Pubmed:8540727]
Antimicrob Agents Chemother. 1995 Sep;39(9):2120-2.
It has been observed that herpes simplex virus mutants with deficient or altered thymidine kinase activity are more susceptible to Cidofovir (CDV; 1-[(S)-3-hydroxy-2-(phosphonomethoxy)propyl]cytosine dihydrate) in tissue culture than are the parental strains. During infection of cells, the elevation of the dCTP pool by thymidine kinase mutant viruses is less than that induced by the wild-type virus. The competition between CDV diphosphate and dCTP at the viral polymerase is therefore changed in favor of CDV diphosphate, enhancing its activity.
Iritis and hypotony after treatment with intravenous cidofovir for cytomegalovirus retinitis.[Pubmed:9194724]
Arch Ophthalmol. 1997 Jun;115(6):733-7.
OBJECTIVE: To describe intraocular inflammation due to treatment with intravenous Cidofovir dihydrate for cytomegalovirus retinitis. DESIGN: Retrospective cohort. SETTING: Three university outpatient ophthalmology clinics. PATIENTS: All patients treated with intravenous cidofovir therapy before October 31, 1996. INTERVENTION: Treatment with intravenous cidofovir was given according to standardized protocols. Intraocular inflammation was treated according to the best medical judgment. MAIN OUTCOME MEASURES: The presence of new intraocular inflammation, the severity of inflammation, visual acuity, and intraocular pressure. RESULTS: Eleven cases of iritis (26%) occurred among 43 patients. In 6 cases, the iritis was bilateral. Patients who experienced iritis were more likely to have been previously treated for cytomegalovirus retinitis (P = .03), to be diabetic (P = .05), or to be receiving protease inhibitors (P < .001). Four patients and 15 control subjects had also taken rifabutin (P = .70). The onset of iritis occurred at a mean (+/-SD) of 4.9 +/- 1.8 days after a cidofovir dose and after a mean (+/-SD) of 4.2 +/- 1.6 doses of cidofovir. Six eyes of 4 patients had hypotony. Five eyes of 5 patients had a persistent decrease in visual acuity of at least 2 Snellen lines. CONCLUSIONS: Acute intraocular inflammation may occur with or without hypotony after intravenous cidofovir therapy, similar to the reactions seen after intravitreous administration. Although the manifestations may be severe, they are manageable with topical corticosteroid therapy in most cases. Cidofovir therapy can be continued in some patients if medical necessity warrants, but recurrent inflammation or permanent hypotony may occur.
Intraocular pressure and aqueous humor dynamics in patients with AIDS treated with intravitreal cidofovir (HPMPC) for cytomegalovirus retinitis.[Pubmed:9262540]
Am J Ophthalmol. 1997 Aug;124(2):168-80.
PURPOSE: To evaluate the decrease in intraocular pressure associated with cidofovir (1-[(S)-3-hydroxy-2-(phosphonomethoxy)propyl]cytosine dihydrate; HPMPC) intravitreal injections. METHODS: We followed up 97 eyes of 63 patients with acquired immunodeficiency syndrome (AIDS) who had cytomegalovirus retinitis and had been treated with up to nine 20-microgram intravitreal cidofovir injections. Measurements were taken at baseline, between 2 and 3 weeks, and at 5 to 6 weeks after injections. Anterior chamber fluorophotometry was studied in seven eyes (four patients) before and after injections. Ciliary body anatomy was evaluated in two patients. RESULTS: After the first intravitreal injection, mean intraocular pressure was 2.2 mm Hg lower than that at baseline at 2 to 3 weeks (P < .001) and 1.3 mm Hg lower than at baseline at 5 to 6 weeks (P = .0025). After the second injection, mean pressure was 2.6 mm Hg lower at 2 to 3 weeks (P = .0013) and 1.5 mm Hg lower at 5 to 6 weeks (P = .043). After subsequent injections, however, the decrease was less than 1 mm Hg, suggesting that a plateau had been reached. Pressure in eyes with anterior uveitis after the first injection was lower than that in eyes without anterior uveitis (P < .0001). The mean rate of aqueous flow decreased from 2.8 to 1.9 microliters per minute 2 to 4 weeks after injection (P < .015). Ultrasound biomicroscopy disclosed that severe hypotony after cidofovir injections is associated with ciliary body atrophy. CONCLUSIONS: Intraocular pressure decreases after the initial 20-microgram cidofovir intravitreal injection. However, eyes stabilize (pressure plateaus) after three injections. Effects on the ciliary body are the main cause of the decrease after cidofovir injections.
Evaluation of Cidofovir (HPMPC, GS-504) against adenovirus type 5 infection in vitro and in a New Zealand rabbit ocular model.[Pubmed:8811201]
Antiviral Res. 1996 Jul;31(3):165-72.
The antiviral inhibitory activity of Cidofovir [1-[(S)-3-hydroxy-2-(phosphonomethoxy)propyl]cytosine dihydrate, HPMPC, GS-504] against adenovirus type 5 (Ad5) in the New Zealand rabbit ocular replication model was evaluated. The 50% inhibitory dose (ID50) of Cidofovir was determined to be 4.7-9.5 micrograms/ml against four adenoviruses (two Ad5, Ad8 and Ad14) by plaque reduction assay in A549 cells. Twenty-four New Zealand rabbits received intrastromal inoculation and topical application of 2 x 10(6) plaque-forming units (PFU) per eye of Ad5 McEwen, a clinical isolate. Cidofovir was administered topically at three different concentrations twice per day, beginning 16 h postinoculation and continuing for 20 consecutive days. The inhibitory effects were determined by measuring suppression of virus replication and by observation of the clinical effects. Compared to the placebo group, the 1% and 0.5% Cidofovir-treated groups showed significantly reduced Ad5 ocular titers, fewer days of viral shedding and less severe subepithelial opacities (P = 0.0001). The 1% Cidofovir group had the lowest humoral antibody titer against adenovirus antigens, but the difference was not significant (P = 0.24). Cidofovir proved to have potent antiviral activity against adenovirus replication and may have great promise for the treatment of adenovirus infection. Further investigation is recommended.
